Success with medicines “Made in Regensburg”
Amareg stands for Medicines from Regensburg and emerged in Regensburg stemming originally from the concern Bristol-Meyers Squibb closed in the 1990s. Since the location has been part of the Berlin Haupt Pharma AG, a contract manufacturer for the pharmaceutical industry, things have been constantly on the up and up. As reported in depth recently by the Mittelbayerische Zeitung, Haupt Pharma is one of the market leaders in Europe in the field of pharmaceutical contract development and manufacturing, know as CMO (Contract Manufacturing Organization). Regensburg is one of nine production locations in Germany, Italy, France and Japan.
The enterprise expects for this year a turnover of 280 million € and employs a total of 2000 people. At Haupt Pharma Amareg GmbH’s site there are currently building projects underway putting production premises into operation with an investment volume of 15 million €. The number of employees is planned to be increased to 360. In particular growth will occur in developing highly potent medicines. This means substances which inhibit cell growth and can be used to treat cancer. In this field of cytostatics the experts are counting on strong growth, particularly in the USA and in Asia. Last year the site was authorised via an inspection by the US Food and Drug Administration (FDA) as a supplier for the US market. Haupt Pharma Amareg GmbH has enriched the BioRegion Regensburg with these activities.
For more information see: